Press Release Details

Cerus Announces Agreement to Supply the INTERCEPT Blood System for Platelets to French National Blood Service

June, 26 2007

France Completes First Step to Adopt the Platelet System

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that it has signed an initial two-year agreement with the French national blood service, Etablissement Francais du Sang (EFS), for the INTERCEPT Blood System for platelets. The terms of the agreement provide for INTERCEPT equipment and disposable purchases of up to $8.0 million, with the actual amounts determined by the rate of implementation in EFS regional centers.

"We are pleased to complete our first formal agreement with EFS. This multi-year contract provides the framework to extend use of the INTERCEPT platelet system from four French regions currently using the system, Alsace and three overseas regions, to broad national adoption over time,'' said Claes Glassell, president and chief executive officer of Cerus Corporation. "The INTERCEPT Blood System will allow France to further improve the safety of platelet transfusions, decreasing the risk from bacteria and emerging pathogens such as Chikungunya, avian flu or West Nile virus."

By mandate of the French government, EFS is responsible for all activities related to collection, preparation, qualification and distribution to hospitals of labile blood product in France. EFS is composed of 18 regional organizations (14 in continental France and four overseas departments). More than 230,000 units of platelet concentrates are transfused each year in France.

INTERCEPT Platelet System

The INTERCEPT Blood System for platelets has received CE mark approval and is produced to ISO quality standards. Platelets treated with the INTERCEPT system have been approved by the Agence Franccaise de Securite Sanitaire des Produits de Sante, the national health and safety regulatory agency for medical products in France, and characteristics of the treated platelets have been approved and published in the Official Journal. Earlier this year, a German blood center received the first marketing authorization for INTERCEPT platelets from the Paul Ehrlich Institute, the agency that regulates blood components in Germany. Over 80,000 INTERCEPT platelet kits have been shipped to date, and the system has been used clinically in over 40 European blood centers.

The INTERCEPT Blood System

The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens, such as viruses, bacteria, and parasites that may be present in donated blood intended for transfusion. The system inactivates pathogens in platelets and plasma using the same illumination device, process and active compound. The INTERCEPT Blood System has received CE mark approvals in Europe for both the platelet and plasma systems. A Phase I clinical trial of the INTERCEPT Blood System for red cells has been completed in the United States.

ABOUT CERUS

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy designed to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology. The system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in the research and development of prophylactic and therapeutic vaccines for infectious diseases.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600